The FDA has approved Novo Nordisk’s Ozempic, a once-weekly injection for type 2 diabetes.
Ozempic consists of a weekly injection of semaglutide, which belongs to a type of drugs known as glucagon-like peptide 1 (GLP-1) receptor agonists.
In October, an FDA panel had voted unanimously in favor of the treatment. Trials included favorable head-to-head data against Eli Lilly’s rival drug, Trulicity, which is already on the market.
Analysts, using Thomson Reuters data, expect annual Ozempic, sales to reach $3.17 billion by 2023, with sales of Trulicity, rising to $3.71 billion.
Read the press release